Zentalis Pharmaceuticals (ZNTL)

About Zentalis Pharmaceuticals (ZNTL)

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals News